PURPOSE: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer focusing on the progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). PATIENTS AND METHODS: A total of 819 patients with ER-positive, operable breast cancer were enrolled. All patients received upfront adjuvant tamoxifen, as stipulated by eligibility criteria. Prognostic values of the PR status and HER2 status were evaluated using Cox regression. RESULTS: Of all patients enrolled, 72% were PR positive and 20% were HER2 positive. PR and HER2 status were inversely correlated (P = 0.014). PR-negative tumors were associated with older age over 50 years (P < 0.001) and higher histologic grade (P = 0.024). HER2 overexpression correlated with older age over 50 years (P = 0.007), higher T stage (P = 0.010), and higher histologic grade (P = 0.047). For recurrence, PR negativity was a poor prognostic factor before 5 years postsurgery (hazard ratio = 1.57; P = 0.049) and HER2 overexpression was a consistent poor prognostic factor over all time periods (hazard ratio = 1.93; P = 0.001) in the multivariate model adjusted by age, T/N stage, and histologic grade. CONCLUSIONS: In ER-positive, operable breast cancer, PR negativity may provide additional information on poor prognosis or tamoxifen resistance during adjuvant tamoxifen therapy within 5 years postsurgery. HER2 overexpression was a poor prognostic factor consistently throughout time. This suggests that an alternative adjuvant strategy, possibly incorporating prolonged HER2-targeted therapy, needs to be evaluated for HER2-overexpressing tumors.
PURPOSE: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer focusing on the progesterone receptor (PR) and humanepidermal growth factor receptor 2 (HER2). PATIENTS AND METHODS: A total of 819 patients with ER-positive, operable breast cancer were enrolled. All patients received upfront adjuvant tamoxifen, as stipulated by eligibility criteria. Prognostic values of the PR status and HER2 status were evaluated using Cox regression. RESULTS: Of all patients enrolled, 72% were PR positive and 20% were HER2 positive. PR and HER2 status were inversely correlated (P = 0.014). PR-negative tumors were associated with older age over 50 years (P < 0.001) and higher histologic grade (P = 0.024). HER2 overexpression correlated with older age over 50 years (P = 0.007), higher T stage (P = 0.010), and higher histologic grade (P = 0.047). For recurrence, PR negativity was a poor prognostic factor before 5 years postsurgery (hazard ratio = 1.57; P = 0.049) and HER2 overexpression was a consistent poor prognostic factor over all time periods (hazard ratio = 1.93; P = 0.001) in the multivariate model adjusted by age, T/N stage, and histologic grade. CONCLUSIONS: In ER-positive, operable breast cancer, PR negativity may provide additional information on poor prognosis or tamoxifen resistance during adjuvant tamoxifen therapy within 5 years postsurgery. HER2 overexpression was a poor prognostic factor consistently throughout time. This suggests that an alternative adjuvant strategy, possibly incorporating prolonged HER2-targeted therapy, needs to be evaluated for HER2-overexpressing tumors.
Authors: Ivo A Olivotto; Pauline T Truong; Caroline H Speers; Vanessa Bernstein; Sharon J Allan; Seamus J Kelly; Mary L Lesperance Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: R Ponzone; F Montemurro; F Maggiorotto; C Robba; D Gregori; M E Jacomuzzi; F Kubatzki; D Marenco; A Dominguez; N Biglia; P Sismondi Journal: Ann Oncol Date: 2006-09-15 Impact factor: 32.976
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Valerie-Jeanne Bardou; Grazia Arpino; Richard M Elledge; C Kent Osborne; Gary M Clark Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Veronique M Neumeister; Valsamo Anagnostou; Summar Siddiqui; Allison Michal England; Elizabeth R Zarrella; Maria Vassilakopoulou; Fabio Parisi; Yuval Kluger; David G Hicks; David L Rimm Journal: J Natl Cancer Inst Date: 2012-10-22 Impact factor: 13.506
Authors: Y Sunakawa; S Cao; M D Berger; S Matsusaka; D Yang; W Zhang; Y Ning; A Parekh; S Stremitzer; A Mendez; S Okazaki; T Wakatsuki; M Azuma; K Shimada; M Watanabe; W Koizumi; A H Wu; H-J Lenz Journal: Pharmacogenomics J Date: 2015-10-27 Impact factor: 3.550
Authors: Ndiya Ogba; Nicole G Manning; Brian S Bliesner; S Kelly Ambler; James M Haughian; Mauricio P Pinto; Paul Jedlicka; Kristiina Joensuu; Päivi Heikkilä; Kathryn B Horwitz Journal: Breast Cancer Res Date: 2014-12-05 Impact factor: 6.466